AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05609084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Speech therapy assessment
Description: Patients will be followed by an speech therapist
Study NCT06352320 — intervention group
Intervention type: BIOLOGICAL
Intervention: Diagnosis of HCM
Description: Hypertrophic cardiomyopathy (HCM) is defined as the presence of increased LV wall thickness (with or without RV hypertrophy) or mass that is not solely explained by abnormal loading conditions.
Study NCT06352320 — intervention group
Intervention type: BIOLOGICAL
Intervention: Diagnosis of DCM
Description: Dilated cardiomyopathy (DCM) is defined as the presence of LV dilatation and global or regional systolic dysfunction unexplained solely by abnormal loading conditions (e.g. hypertension, valve disease, CHD) or CAD.Very rarely, LV dilatation can occur with normal ejection fraction (EF) in the absence of athletic remodelling or other environmental factors; this is not in itself a cardiomyopathy, but may represent an early manifestation of DCM. The preferred term for this is isolated left ventricular dilatation. Right ventricular dilatation and dysfunction may be present but are not necessary for the diagnosis.
Study NCT06352320 — intervention group
Intervention type: BIOLOGICAL
Intervention: Diagnosis of ARVC
Description: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is defined as the presence of predominantly RV dilatation and/or dysfunction in the presence of histological involvement and/or electrocardiographic abnormalities in accordance with published criteria.
Study NCT06352320 — intervention group
Intervention type: BIOLOGICAL
Intervention: Diagnosis of NDLVC
Description: The NDLVC phenotype is defined as the presence of non-ischaemic LV scarring or fatty replacement regardless of the presence of global or regional wall motion abnormalities (RWMAs), or isolated global LV hypokinesia without scarring.
Study NCT06352320 — intervention group
Intervention type: BIOLOGICAL
Intervention: Diagnosis of RCM
Description: Restrictive cardiomyopathy (RCM) is defined as restrictive left and/or RV pathophysiology in the presence of normal or reduced diastolic volumes (of one or both ventricles), normal or reduced systolic volumes, and normal ventricular wall thickness.Restrictive cardiomyopathy commonly presents as biatrial enlargement. Left ventricular systolic function can be preserved, but it is rare for contractility to be completely normal. Restrictive pathophysiology may not be present throughout the natural history, but only at an initial stage (with an evolution towards a hypokinetic-dilated phase). Restrictive physiology can also occur in patients with end-stage hypertrophic and dilated cardiomyopathy; the preferred terms are 'hypertrophic' or 'dilated cardiomyopathy with restrictive physiology'. Restrictive ventricular physiology can also be caused by endocardial pathology (fibrosis, fibroelastosis, and thrombosis) that impairs diastolic function
Study NCT06352320 — intervention group
Intervention type: BIOLOGICAL
Intervention: Diagnosis of LVNC
Description: The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickerendocardial layer. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope. Left ventricular non-compaction has also been used to describe an acquired and sometimes transient phenomenon of excessive LV trabeculation (e.g. in athletes, during pregnancy, or following vigorous activity)that must reflect increased prominence of an otherwise normal myocardial architecture, given that cardiomyocytes are terminally differentiated and the formation of new cardiac structures is impossible.The Task Force does not consider LVNC to be a cardiomyopathy in the general sense.
Study NCT06271811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flossing band
Description: The application of flossing to the knee commences with a preliminary evaluation of the joint range of motion and pain perception. The band is wrapped around the knee, starting with an approximate tension of 50% for the first wrap and escalating to a tension of 60-80% in subsequent wraps. It\&#39;s essential to overlap the band with each wrap, moving from a distal to the proximal direction (bottom to top), which aids in enhancing drainage. Continuous monitoring of the patient is critical to ensure that excessive pressure is not being applied. This can be achieved by palpating the pulse on the dorsum of the foot or inner ankle, and observing if the skin regains its normal color after pressing the area with fingers. Should the patient experience strong tingling or pain, the bandage must be immediately removed. The duration of the band's application varies between 2 to 5 minutes, depending on patient tolerance, a methodology informed by existing research.
Study NCT06271811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: The intervention protocol is centered on neuromuscular training, targeting the strengthening of key muscle groups including the quadriceps, hamstrings, and hip abductors, which are vital for knee stabilization. This approach is supported by previous research, emphasizing the importance of these muscle groups in knee joint health. Complementing this, proprioceptive exercises, such as single-leg balances and controlled knee bends, were incorporated to enhance joint position sense, aligning with the guidelines set forth by Powers et al., 2010.~The intensity of these exercises is progressively increased, tailored to each patient's tolerance and improvement. The protocol stipulates two sessions per week over eight weeks.
Study NCT04843930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKL-T01
Description: AKL-T01 will be administered as a 6-week intervention. It is an algorithmically delivered iPad-based video game designed to improve cognitive health by targeting attention and attentional control processes.
Study NCT04755101 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EPS, electro-anatomical mapping, ARGP ablation, and pharmacological evaluation.
Description: EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. Sequential ablations will be delivered along theTL until the procedure endpoint is reached. Pharmacological evaluation.
Study NCT04755101 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: EPS, electro-anatomical mapping, and pharmacological evaluation.
Description: EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. No ablation is performed (sham). Pharmacological evaluation.
Study NCT05724355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib Isetionate Tablets, Camrelizumab
Description: Dalpiciclib, D1-21, po, 150mg, qd, Q4W. Camrelizumab, iv, 200mg, D1, Q3W.
Study NCT00669786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Menopausal Gonadotropin (HMG) & - Recombinant Follicle Stimulating Hormone (r-FSH)
Study NCT06275152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
Study NCT06275152 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Conditioning
Description: The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
Study NCT04920864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation
Study NCT04920864 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation
Study NCT05917639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitruvian plot
Description: Visual (magnitude, uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
Study NCT05917639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kilim plot
Description: Visual (uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
Study NCT05917639 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Summary of findings table
Description: Written (magnitude, uncertainty) communication tool / interventional decision-making aid tool
Study NCT06118268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS (Active)
Description: The present study is a double-blind, randomized clinical trial that will examine if iTBS applied to DMPFC improves social cognitive performance compared to sham stimulation~DMPFC-iTBS will be administered using the MagPro R30 stimulator equipped with a Cool-B70 coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies Enschede, Netherlands).
Study NCT06118268 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iTBS (Sham)
Description: DMPFC-iTBS will be administered using the MagPro R30 stimulator equipped with a Cool-B70 coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies Enschede, Netherlands).
Study NCT04369014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate anesthesia
Description: etomidate is used for induction and maintenance of general anesthesia
Study NCT04369014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol anesthesia
Description: propofol is used for induction and maintenance of general anesthesia
Study NCT05207514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoxel M
Description: 75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
Study NCT05207514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere
Description: 75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
Study NCT05207514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with cyclophosphamide
Study NCT05207514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with cyclophosphamide
Study NCT05207514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with doxorubicin.
Study NCT05207514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with doxorubicin.
Study NCT06344390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Take pentoxifylline 0.4 g twice daily
Study NCT06336616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Activation
Description: Participants will be taught to identify meaningful activities, set goals, use environmental cues, self-reward, to identify barriers and facilitators, and learn new skills to support them to develop self-management skills and new habits.
Study NCT05597657 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fluid administration (Fresenius Kabi Sodium Chloride 0.9%)
Description: All participants in substudy 2 will be administered 2 liters of isotonic saline infusion (Fresenius Kabi Sodium Chloride 0.9%) intravenously. CMR and echocardiography will be performed before and after infusion.
Study NCT05056779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants will receive loading dose of 60 milligram (2×30 mg) subcutaneous (SC) injection of nemolizumab at baseline. Thereafter 30 mg nemolizumab will be administered via single SC injection once in 4 week (Q4W) up to week 12.
Study NCT05056779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD14152 placebo
Description: Participants will receive loading dose of 60 mg (2×30 mg) SC injection of placebo at baseline. Thereafter 30 mg placebo will be administered via single SC injection Q4W up to week 12.
Study NCT04816513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Ustekinumab will be administered as SC injection.
Study NCT04816513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered as SC injection.
Study NCT04885556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tampon-like device for absorption of sexual fluids
Description: Subjects will insert a tampon-like device to absorb sexual fluids after intercourse
Study NCT05980182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Application
Description: Self-directed application (app) that is downloaded to the participant's personal device. The app contains five informational videos, that provide an orientation to the content on the app, and discuss what colorectal cancer is, and the type of CRC screening tests that are available as well as a video with a personal history. There is a a National Cancer Institute (NCI) risk calculation tool, and a family history infographic. Once the videos have been viewed participants have the option to indicate if they wish to receive a call from the healthcare clinic to discuss scheduling an appointment for screening.
Study NCT05159089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socioecological model apply to reduce physical activity drop out in type 2 diabetes patients
Description: To implement this model this intervention aims to address three key elements: 1) prepare the user; 2) structure the action; and 3) design the context.~These goals will be worked in each session of Nordic Walking during the warm-up and cool-down and, if necessary, during the session (as long as it's non-stop or slowing down).
Study NCT05159089 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nordic Walking
Description: Sessions will be progressive: the first month will long 30 minutes, the second month 35 minutes, and the third month 40 minutes (without 10 minutes warm-up and 10 minutes cool-down each session). The track will not have more than 100 accumulate high and will allow doing 5 kilometers without stopping. The meeting point will be between the Biomedical Research Park (Barcelona) and Hospital del Mar (nearby CAP Sant Joan). All sessions will be conducted by an instructor of nordic walking physiotherapists.
Study NCT06545981 — intervention group
Intervention type: OTHER
Intervention: Lumbar puncture and administration of medication
Description: Patients with idiopathic intracranial hypertension will receive lumbar puncture and will be given medication to reduce intracranial pressure by neurologists. The lumbar puncture and the administration of medication are not part of this study, patients would also receive these without participating in the study.
Study NCT04258488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban Oral Tablet
Description: For 12months, Rivaroxaban oral tablet 20mg once daily For renal disorder subjects_creatinine clearance 15-49 mL/min, 15mg once daily
Study NCT05388721 — intervention group
Intervention type: OTHER
Intervention: Clinical data and specimen collection
Description: Questionnaire survey and clinical data was conducted when pregnant women were enrolled in the first trimester, and blood and urine were collected. Furthermore, we will follow up the pregnant women until delivery, blood and urine were collected during the third trimester (after 28 weeks), and clinical information was collected.~Umbilical cord blood and placental tissue will be collected if possible.
Study NCT05100186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.4 MG [Dextenza]
Description: Dextenza
Study NCT00914004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine HCl 50 mg Tablets Cord Laboratories
Study NCT00914004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc
Study NCT05952635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tip bendable suction ureteral access sheath
Description: Patient use tip bendable suction ureteral access sheath during flexible ureteroscopy to see if flexible ureteroscopy with S-UAS offers the better treatment outcomes in terms of clinical effectiveness and post-operative complications.
Study NCT06495203 — intervention group
Intervention type: DRUG
Intervention: anti-VEGF treatment
Description: Follow clinical practice/administration
Study NCT04813380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual immunotherapy
Description: Sublingual immunotherapy give to allergic rhinitis patients for treatment
Study NCT04813380 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sublingual immunotherapy
Description: Sublingual immunotherapy give to allergic rhinitis patients for treatment
Study NCT05399680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S.M.A.R.T. RADIANZ™ Vascular Stent System
Description: The S.M.A.R.T. RADIANZ™ Vascular Stent System is designed to deliver the S.M.A.R.T.™ self-expanding stent (S.M.A.R.T.™ stent) to the iliac arteries, superficial femoral arteries and/or proximal popliteal arteries using a 6F (2.0 mm) sheathed delivery system introduced through the radial artery.
Study NCT05399680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRITE TIP RADIANZ™ Guiding Sheath
Description: BRITE TIP RADIANZ™ is a catheter guiding sheath that facilitates percutaneous entry of an intravascular device into the peripheral vasculature through the radial artery.
Study NCT05399680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SABERX RADIANZ™ PTA Balloon Catheter
Description: SABERX RADIANZ™ is a catheter with a distal inflatable balloon.
Study NCT04965350 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
Description: sterile solution for intramuscular injection
Study NCT04965350 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
Description: sterile solution for intramuscular injection
Study NCT05261893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elongation Longitudinaux Avec Decoaption Osteo Articulaire
Description: It creates tension in the spine and stretch the fascia and is a myofascial stretch technique and manual physical therapy tool
Study NCT05261893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Facilitation Stretching
Description: Post Facilitation Stretching effectively decreases hamstring muscle tightness while also increasing popliteal angle range. Post-facilitation exercise can help to relieve knee pain. It effectively raises ROM or aligns collagen fibers due to the muscle contraction performed immediately before stretching.
Study NCT05183022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total30 Sphere Contact Lenses
Description: Participants will be refit into Total30 Sphere contact lenses and followed for 1 month.
Study NCT06192082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The conscious sedation group
Description: The conscious sedation group (Group A) received sufentanil 0.05-0.1 5 minutes before examination μ G/kg, administration time 30 seconds, 1-2 mg of midazolam administered 2 minutes before examination; Evaluate the patient's MOAA/S score, insert a digestive endoscope at 2-3 minutes, and add 1-2mg of midazolam if the patient is unable to tolerate coughing or movement during the examination. Reevaluate the MOAA/S score, and continue the operation after 2-3 minutes;
Study NCT06192082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous general anesthesia group
Description: Intravenous general anesthesia group (Group B): sufentanil 0.05-0.1 μ G/kg, administration time 30 seconds, 1mg/kg of propofol administered 2 minutes before examination. Depending on the patient's sleep status, 10mg of propofol can be administered every 30 seconds; Evaluate the patient's MOAA/S score. At 0-1 points, a digestive endoscope is inserted. If there is coughing or physical activity during the examination that the patient cannot tolerate, propofol 10-20mg can be administered multiple times. Evaluate the MOAA/S score again, and continue the operation after 0-1 points.
Study NCT06020092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone augmentation with I-BCP
Description: The extraction socket will be filled after tooth extraction with I-BCP, in order to achieve bone regeneration and prevent volume loss after tooth extraction.
Study NCT06020092 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone augmentation with BX
Description: The extraction socket will be filled after tooth extraction with BX, in order to achieve bone regeneration and prevent volume loss after tooth extraction.
Study NCT05982184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Patient preferred music listened to through earpieces or headphones using patients' own hardware and software.